Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00218023 · ClinicalTrials.gov registry record · Phase 2

Medications for Stopping Cocaine Dependence and Preventing Relapse

A Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 2
Development phase
101
Enrollment target

NCT00218023: Completed Phase 2 study, sponsored by The University of Texas Health Science Center, Houston.

NCT00218023 is a Phase 2 study that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 101 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00218023, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 2
Development phase
101 participants
Enrollment target

Study Summary

Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to identify subpopulations and baseline conditions that are most responsive to treatment for cocaine dependent individuals.

Primary Outcome

Cocaine use was determined by assessing for the presence of benzoylecgonine in urine.

Interventions

  • DRUG Placebo
  • DRUG Modafinil
  • BEHAVIORAL Motivational Interviewing (MI)
  • DRUG Levodopa/Carbidopa
  • DRUG Naltrexone HCl

Trial Details

FieldValue
Enrollment Target 101 participants
Start Date 2006-03
Est. Completion 2012-04
Phase Phase 2

What the finished NCT00218023 record still lists

NCT00218023 is an interventional study that assigns participants to a tested intervention. The registered 101 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (24% lower).

The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.

NCT00218023 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT00218023 about?

NCT00218023 is a clinical study titled "Medications for Stopping Cocaine Dependence and Preventing Relapse". Cocaine dependence is a major public health problem; an effective primary treatment for cocaine dependent individuals has yet to be found. The purpose of this study is to identify subpopulations and baseline conditions that are most responsive to treatment for cocaine dependent individuals.

What is the current status of trial NCT00218023?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 101 participants. The study started on 2006-03. Estimated completion is 2012-04.

What interventions are being tested in trial NCT00218023?

The interventions under investigation include: Placebo (DRUG), Modafinil (DRUG), Motivational Interviewing (MI) (BEHAVIORAL), Levodopa/Carbidopa (DRUG), Naltrexone HCl (DRUG).

Who is sponsoring clinical trial NCT00218023?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT00218023's enrollment target sits among peer trials

101 672nd of 2000 higher than 1,329 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04033497 · 101 participants · NA

    Treatment Response Assessment Maps to Delineate Necrosis From Tumor After Stereotactic Radiation in Brain Metastases

  • NCT05111574 · 101 participants · Phase 2

    Using Nivolumab Alone or With Cabozantinib to Prevent Mucosal Melanoma Return After Surgery

  • NCT05984680 · 101 participants

    COPD Care Pathway Among Patients With Cancer

  • NCT06266299 · 101 participants · Phase 1

    A Study of KK2269 in Adult Participants With Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00218023, the US trial registry maintained by the National Library of Medicine. NCT00218023 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.